Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Outstanding (Diluted Average) (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $56.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 5.15% to $56.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $56.1 million, a 5.15% increase, with the full-year FY2024 number at $53.9 million, up 37.86% from a year prior.
  • Shares Outstanding (Diluted Average) was $56.1 million for Q3 2025 at 4D Molecular Therapeutics, roughly flat from $55.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $56.1 million in Q3 2025 to a low of $26.7 million in Q2 2021.
  • A 5-year average of $41.1 million and a median of $38.7 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): grew 1.52% in 2023, then skyrocketed 50.57% in 2024.
  • 4D Molecular Therapeutics' Shares Outstanding (Diluted Average) stood at $27.7 million in 2021, then rose by 16.66% to $32.4 million in 2022, then rose by 20.95% to $39.1 million in 2023, then skyrocketed by 37.86% to $53.9 million in 2024, then grew by 4.05% to $56.1 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Shares Outstanding (Diluted Average) are $56.1 million (Q3 2025), $55.9 million (Q2 2025), and $55.7 million (Q1 2025).